BR112022004495A8 - Compostos oxinitreto de piridina, composição farmacêutica compreendendo os mesmos e usos dos mesmos - Google Patents
Compostos oxinitreto de piridina, composição farmacêutica compreendendo os mesmos e usos dos mesmosInfo
- Publication number
- BR112022004495A8 BR112022004495A8 BR112022004495A BR112022004495A BR112022004495A8 BR 112022004495 A8 BR112022004495 A8 BR 112022004495A8 BR 112022004495 A BR112022004495 A BR 112022004495A BR 112022004495 A BR112022004495 A BR 112022004495A BR 112022004495 A8 BR112022004495 A8 BR 112022004495A8
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- pharmaceutical composition
- pyridine
- oxinitide
- composition including
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/22—Nitrogen and oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910863718 | 2019-09-12 | ||
| CN201911094782 | 2019-11-11 | ||
| CN202010531381 | 2020-06-11 | ||
| CN202010923311 | 2020-09-04 | ||
| PCT/CN2020/114700 WO2021047622A1 (zh) | 2019-09-12 | 2020-09-11 | 吡啶氮氧化合物及其制备方法和用途 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112022004495A2 BR112022004495A2 (pt) | 2022-05-31 |
| BR112022004495A8 true BR112022004495A8 (pt) | 2023-04-18 |
Family
ID=74866555
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022004495A BR112022004495A8 (pt) | 2019-09-12 | 2020-09-11 | Compostos oxinitreto de piridina, composição farmacêutica compreendendo os mesmos e usos dos mesmos |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20230303495A9 (https=) |
| EP (1) | EP4043437A4 (https=) |
| JP (1) | JP2022548104A (https=) |
| KR (1) | KR20220101606A (https=) |
| CN (3) | CN118146148A (https=) |
| AU (1) | AU2020346951A1 (https=) |
| BR (1) | BR112022004495A8 (https=) |
| CA (1) | CA3150400A1 (https=) |
| CL (1) | CL2022000619A1 (https=) |
| CO (1) | CO2022004594A2 (https=) |
| GE (2) | GEP20247688B (https=) |
| MX (1) | MX2022003032A (https=) |
| PE (1) | PE20221515A1 (https=) |
| PH (1) | PH12022550584A1 (https=) |
| TW (1) | TWI770607B (https=) |
| WO (1) | WO2021047622A1 (https=) |
| ZA (1) | ZA202204100B (https=) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116829539B (zh) * | 2021-03-11 | 2025-11-25 | 上海济煜医药科技股份有限公司 | 吡啶氮氧化合物晶型及其应用 |
| HRP20260068T1 (hr) | 2021-06-04 | 2026-02-27 | Vertex Pharmaceuticals Incorporated | Čvrsti farmaceutski oblici i režimi doziranja koji obuhvaćaju (2r,3s,4s,5r)-4-[[3-(3,4-difluor-2-metoksifenil)-4,5-dimetil-5-(trifluormetil)tetrahidrofuran-2-karbonil]amino]piridin-2-karboksamid |
| CA3221938A1 (en) | 2021-06-04 | 2022-12-08 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofuran analogs as modulators of sodium channels |
| AU2022283934A1 (en) | 2021-06-04 | 2023-11-30 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofuran-2-carboxamides as modulators of sodium channels |
| SMT202500481T1 (it) | 2021-06-04 | 2026-01-12 | Vertex Pharma | N-(idrossialchil(etero)aril)tetraidrofuran carbossammidi come modulatori di canali del sodio |
| US20240400544A1 (en) | 2021-06-04 | 2024-12-05 | Vertex Pharmaceuticals Incorporated | N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamide analogs as modulators of sodium channels |
| WO2022256842A1 (en) | 2021-06-04 | 2022-12-08 | Vertex Pharmaceuticals Incorporated | Hydroxy and (halo)alkoxy substituted tetrahydrofurans as modulators of sodium channels |
| MX2024008057A (es) | 2021-12-30 | 2024-08-28 | Biomea Fusion Inc | Compuestos de pirazina como inhibidores de flt3. |
| CN116891432A (zh) * | 2022-04-02 | 2023-10-17 | 武汉人福创新药物研发中心有限公司 | Nav1.8抑制剂及其用途 |
| US20230382910A1 (en) | 2022-04-22 | 2023-11-30 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| CA3257285A1 (en) | 2022-04-22 | 2023-10-26 | Vertex Pharmaceuticals Incorporated | HETEROARYL COMPOUNDS FOR PAIN RELIEF |
| WO2023205463A1 (en) | 2022-04-22 | 2023-10-26 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| CA3256248A1 (en) | 2022-04-22 | 2023-10-26 | Vertex Pharmaceuticals Incorporated | HETEROARYL COMPOUNDS FOR PAIN RELIEF |
| WO2023232117A1 (zh) | 2022-06-02 | 2023-12-07 | 上海济煜医药科技有限公司 | 吡啶氮氧化合物的制备方法 |
| AU2023287273A1 (en) * | 2022-06-22 | 2025-01-09 | Wuhan Humanwell Innovative Drug Research and Development Center Limited Company | Nav1.8 inhibitor |
| WO2024123815A1 (en) | 2022-12-06 | 2024-06-13 | Vertex Pharmaceuticals Incorporated | Process for the synthesis of substituted tetrahydrofuran modulators of sodium channels |
| WO2024153856A1 (en) * | 2023-01-18 | 2024-07-25 | Orion Corporation | Process for the preparation of 3-(4,5-dichloro-2-(4-(trifluoromethoxy)phenoxy)benzamido)pyridine 1-oxide |
| CN121419965A (zh) * | 2023-06-14 | 2026-01-27 | 上海济煜医药科技股份有限公司 | 吡啶氮氧化合物的盐型、共晶及其制备方法和应用 |
| TW202500551A (zh) * | 2023-06-14 | 2025-01-01 | 大陸商上海濟煜醫藥科技有限公司 | 吡啶氮氧化合物與富馬酸的共晶體及其組合物、用途和製備方法 |
| WO2025090516A1 (en) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Methods of preparing compounds for treating pain and solid forms thereof |
| WO2025090511A1 (en) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Methods of preparing modulators of sodium channels and solid forms of the same for treating pain |
| WO2025090480A1 (en) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| WO2025090465A1 (en) | 2023-10-23 | 2025-05-01 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| US20250186419A1 (en) | 2023-12-07 | 2025-06-12 | Vertex Pharmaceuticals Incorporated | Dosing regimens for treating pain |
| WO2025124502A1 (zh) * | 2023-12-13 | 2025-06-19 | 武汉人福创新药物研发中心有限公司 | 一种Nav1.8抑制剂化合物及其盐、多晶型和用途 |
| US20260001877A1 (en) | 2024-06-28 | 2026-01-01 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
| WO2026013449A2 (en) | 2024-07-11 | 2026-01-15 | Sea4Us - Biotecnologia E Recursos Marinhos, Sa | Oxazolidone-derived compounds and their use in the treatment of chronic and acute pain |
| WO2026030525A1 (en) | 2024-07-31 | 2026-02-05 | Vertex Pharmaceuticals Incorporated | Zilvetrigine dosage forms and dosing regimens for treating pain |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5834468A (en) * | 1995-07-07 | 1998-11-10 | Zeneca Limited | Substituted aryl and heteroaryl compounds as E-type prostaglandin antagonists |
| MX295245B (es) * | 2005-06-21 | 2012-01-26 | Mitsui Chemicals Inc | Derivado de amida e insecticida que contiene el mismo. |
| EP2004596A2 (en) * | 2006-04-11 | 2008-12-24 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of voltage-gated sodium channels |
| JP2010047480A (ja) * | 2006-12-19 | 2010-03-04 | Mitsui Chemicals Inc | 虫害の予防方法 |
| KR20100075631A (ko) * | 2007-10-11 | 2010-07-02 | 버텍스 파마슈티칼스 인코포레이티드 | 전압개폐 나트륨 채널의 억제제로서 유용한 아릴 아미드 |
| WO2009049181A1 (en) * | 2007-10-11 | 2009-04-16 | Vertex Pharmaceuticals Incorporated | Amides useful as inhibitors of voltage-gated sodium channels |
| EP2655330B1 (en) * | 2010-12-22 | 2016-02-10 | Purdue Pharma LP | Substituted pyridines as sodium channel blockers |
| RU2683788C2 (ru) * | 2013-01-31 | 2019-04-02 | Вертекс Фармасьютикалз Инкорпорейтед | Амиды хинолина и хиназолина, полезные в качестве модуляторов натриевых каналов |
| CA2898653C (en) * | 2013-01-31 | 2021-09-28 | Vertex Pharmaceuticals Incorporated | Amides as modulators of sodium channels |
| RS56015B1 (sr) * | 2013-01-31 | 2017-09-29 | Vertex Pharma | Piridon amidi kao modulatori natrijumovih kanala |
| CA2931550C (en) * | 2013-12-13 | 2023-09-26 | Vertex Pharmaceuticals Incorporated | Prodrugs of pyridone amides useful as modulators of sodium channels |
| AU2018300150A1 (en) * | 2017-07-11 | 2020-01-30 | Vertex Pharmaceuticals Incorporated | Carboxamides as modulators of sodium channels |
| CA3105657A1 (en) * | 2018-07-09 | 2020-01-16 | Lieber Institute, Inc. | Pyridine carboxamide compounds for inhibiting nav1.8 |
-
2020
- 2020-09-11 BR BR112022004495A patent/BR112022004495A8/pt unknown
- 2020-09-11 AU AU2020346951A patent/AU2020346951A1/en not_active Abandoned
- 2020-09-11 GE GEAP202015928A patent/GEP20247688B/en unknown
- 2020-09-11 CN CN202410255352.5A patent/CN118146148A/zh active Pending
- 2020-09-11 PE PE2022000407A patent/PE20221515A1/es unknown
- 2020-09-11 TW TW109131318A patent/TWI770607B/zh active
- 2020-09-11 CN CN202080037787.2A patent/CN113906013B/zh active Active
- 2020-09-11 WO PCT/CN2020/114700 patent/WO2021047622A1/zh not_active Ceased
- 2020-09-11 PH PH1/2022/550584A patent/PH12022550584A1/en unknown
- 2020-09-11 US US17/642,020 patent/US20230303495A9/en not_active Abandoned
- 2020-09-11 JP JP2022516434A patent/JP2022548104A/ja active Pending
- 2020-09-11 GE GEAP202415928A patent/GEAP202415928A/en unknown
- 2020-09-11 CA CA3150400A patent/CA3150400A1/en active Pending
- 2020-09-11 EP EP20863934.4A patent/EP4043437A4/en active Pending
- 2020-09-11 CN CN202010957957.0A patent/CN112479996B/zh active Active
- 2020-09-11 MX MX2022003032A patent/MX2022003032A/es unknown
- 2020-09-11 KR KR1020227012157A patent/KR20220101606A/ko not_active Ceased
-
2022
- 2022-03-11 CL CL2022000619A patent/CL2022000619A1/es unknown
- 2022-04-11 ZA ZA2022/04100A patent/ZA202204100B/en unknown
- 2022-04-11 CO CONC2022/0004594A patent/CO2022004594A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4043437A1 (en) | 2022-08-17 |
| BR112022004495A2 (pt) | 2022-05-31 |
| US20230026907A1 (en) | 2023-01-26 |
| PE20221515A1 (es) | 2022-10-04 |
| CN113906013B (zh) | 2024-03-12 |
| GEP20247688B (en) | 2024-11-11 |
| MX2022003032A (es) | 2022-07-12 |
| EP4043437A4 (en) | 2023-10-04 |
| CN112479996B (zh) | 2023-05-26 |
| AU2020346951A1 (en) | 2022-04-28 |
| CN112479996A (zh) | 2021-03-12 |
| CN113906013A (zh) | 2022-01-07 |
| KR20220101606A (ko) | 2022-07-19 |
| TWI770607B (zh) | 2022-07-11 |
| WO2021047622A1 (zh) | 2021-03-18 |
| JP2022548104A (ja) | 2022-11-16 |
| PH12022550584A1 (en) | 2024-03-04 |
| GEAP202415928A (en) | 2024-07-10 |
| CL2022000619A1 (es) | 2022-10-28 |
| CN118146148A (zh) | 2024-06-07 |
| CO2022004594A2 (es) | 2022-07-08 |
| US20230303495A9 (en) | 2023-09-28 |
| ZA202204100B (en) | 2024-04-24 |
| CA3150400A1 (en) | 2021-03-18 |
| TW202114990A (zh) | 2021-04-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022004495A8 (pt) | Compostos oxinitreto de piridina, composição farmacêutica compreendendo os mesmos e usos dos mesmos | |
| NZ777871A (en) | Small molecule modulators of il-17 | |
| EA201892395A1 (ru) | Лекарственные составы ингибитора lsd1 | |
| PH12020551870A1 (en) | Tetracyclic heteroaryl compounds | |
| BR112019022512A2 (pt) | Compostos de heteroarila bicíclica fundida 6-6 e seu uso como inibidores de lats | |
| EA201891191A1 (ru) | 2-замещенные соединения хиназолина, содержащие замещенную гетероциклическую группу, и способы их применения | |
| MY205300A (en) | 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f] isoquinoline derivatives useful in the treatment of cancer | |
| EA201691151A1 (ru) | Соединения для лечения пациентов с ros1-мутантными раковыми клетками | |
| BR112018010879A2 (pt) | inibidores da proteína quinase, método de preparação e uso médico dos mesmos | |
| EA201800064A1 (ru) | 1,1,1-трифтор-3-гидроксипропан-2-ил карбаматные производные и 1,1,1-трифтор-4-гидроксибутан-2-ил карбаматные производные в качестве ингибиторов magl | |
| MX2020005518A (es) | Mezclas no racemicas y usos de las mismas. | |
| EA201892075A1 (ru) | Комбинации ингибиторов lsd1 для применения для лечения солидных опухолей | |
| EA202191188A1 (ru) | Бензамиды производных пиразолил-амино-пиримидинила, композиции на их основе и способы применения | |
| MX394588B (es) | Composición farmacéutica. | |
| BR112017010645A2 (pt) | derivados da piridinocarboxamida, método de preparação dos mesmos e usos farmacêuticos dos mesmos | |
| BR112017025851A2 (pt) | compostos de pirazol e pirrol substituídos e métodos para usar os mesmos para inibição de iniciação de tradução e tratamento de doenças e distúrbios relacionados aos mesmo | |
| BR112022021748A2 (pt) | Compostos e composições para inibir a atividade de hif2a e seus métodos de uso | |
| BR112021018707A2 (pt) | Formulações compreendendo melflufeno | |
| BR112022006394A2 (pt) | Derivados heterocíclicos, composições farmacêuticas e seu uso no tratamento ou melhora do câncer | |
| BR112021017957A2 (pt) | Derivado tienoeterocíclico, método de preparação do mesmo e uso médico do mesmo | |
| BR112014032244A2 (pt) | composto, uso de um composto, métodos de prevenção, tratamento, melhora ou profilaxia de distúrbios fisiológicos ou doenças associadas com hiperplasia, neoplasia ou displasia, e de tratamento ou melhora de indicações cosméticas, e, composição farmacêutica | |
| MX2017009853A (es) | Prevencion o tratamiento de enfermedades urinarias o gotosas. | |
| BR112018013408A2 (pt) | derivados de c-glicosídeo que têm anel fenila fusionado ou sais farmaceuticamente aceitáveis dos mesmos, método para preparar os mesmos e composição farmacêutica compreendendo os mesmos | |
| BR112018007720A2 (pt) | novos derivados de piridona e seu uso como inibidores da quinase | |
| BR112015030953A8 (pt) | compostos de piridina fundidos de heterociclo de cinco membros, método de produzir os mesmos, e uso dos mesmos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25A | Requested transfer of rights approved |
Owner name: ORION CORPORATION (FI) |
|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B25A | Requested transfer of rights approved |
Owner name: SHANGHAI JEYOU PHARMACEUTICAL CO., LTD. (CN) |